Developments SIGA signs licencing agreement with Vanderbilt U for mAbs portfolio SIGA Technologies (NASDAQ:SIGA) announced that it has entered into an agreement with Vanderbilt University to license to a portfolio of preclinical, fully human monoclonal antibodies (mAbs), which have the potential... October 22, 2024